(8 years, 8 months ago)
Commons ChamberI welcome the Backbench Business Committee’s selection of this important topic, and I congratulate my hon. Friend the Member for Norwich North (Chloe Smith) and the hon. Members for Kingston upon Hull North (Diana Johnson) and for South Down (Ms Ritchie) on their efforts in securing this valuable debate.
I want to acknowledge the tremendous campaigning work of the all-party parliamentary group on haemophilia and contaminated blood. Its efforts have helped to pave the way for the current Department of Health consultation to secure a lasting financial and support settlement for those thousands of people infected with HIV and hepatitis C through contaminated blood in the 1970s and early 1980s.
Let me say at the outset that my heart goes out to those people who have been affected by the contaminated blood scandal, both in my constituency of South East Cornwall and across the country. The devastating impact on patients and their families and friends is immeasurable and lasts for a lifetime. We must all do what we can to ensure that those affected have as secure a future as possible.
I have personal experience of trying to help one constituent who has sadly been impacted by this terrible tragedy. My constituent was infected with contaminated blood in 1985 at the age of 35 and subsequently contracted full blown hepatitis C, which has now developed into cirrhosis of the liver.
My constituent, who understandably has asked not to be identified, has undergone three courses of arduous interferon-based treatment. The last course caused a life-threatening infection that required a month in hospital and some invasive surgery and extensive abdominal surgery.
Now aged 65, my constituent suffers from severe fatigue, physical weakness, brain fog, which means that she is unable to read anything vaguely complicated, constant itching, fever, sweats, depression and total and permanent hair loss. The stress of living with those conditions on a daily basis for 30 years must be immeasurable. The Government must do all they can to support patients and their families.
My constituent wanted me to highlight her case as an example of where anomalies in support for patients suffering from cirrhosis of the liver have led to financial hardship and additional worry at a very distressing time. She was very grateful for the lump sum she received and an income of £14,760 per annum. However, that figure would be £26,000 in Scotland, nearly double the sum offered in England. That is iniquitous.
A constituent of mine—Janis Richards of Sudbury—has written to me, and hers is a very tragic case similar to that highlighted by my hon. Friend. I am struggling to explain to her why there are such different arrangements for constituents across the United Kingdom, given that this problem originally arose under a UK Government.
I completely concur with my hon. Friend. My constituent is particularly concerned about proposals to withdraw index linking from annual income and to refuse to increase it by any meaningful amount. I understand that there is a recommendation to fix annual payments at a flat rate of £15,000 a year, which would leave my constituent with a nominal financial increase of about £240. There are also proposals to withdraw back-up services for emergencies and to withdraw support, which my constituent will certainly require, given the severity of her condition.
May I ask my hon. Friend the Minister to clarify the position, and to take my constituent’s concerns into account when formulating final proposals? My constituent previously enjoyed a successful career in the legal profession, but she became too ill to pursue it after her infection with contaminated blood. Her career was, sadly, cut short, as was her considerable earning potential and professional development.
Patients must be treated with fairness, and each case must be assessed and supported on its merits. I am grateful that the Prime Minister acknowledged the scale of the tragedy and apologised on behalf of the UK Government. I welcome the additional funding for England that was announced in 2015 to ease the transition to a reformed scheme and ensure its sustainable operation with patients at its core. That scheme must provide a robust and fair system that supports and compensates those who are affected and removes any unnecessary complexity and unfairness.